Business Context and Reporting Period
This Form 8-K was filed by DT Cloud Star Acquisition Corporation on November 26, 2025. The registrant is a Cayman Islands-based special purpose acquisition company (SPAC) with securities trading on The Nasdaq Stock Market LLC under the symbols DTSQU, DTSQ, and DTSQR. The filing reports a corporate governance event occurring on the date of the report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of a new director to the Company's board of directors.
- Event: Appointment of Dr. Xunyong Zhou as a director.
- Date: November 26, 2025.
- Context: Dr. Zhou brings over 6 years of experience in biotechnology and health innovation, with expertise in enzyme-based theory, cell therapy, and AI-enhanced health solutions.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, management commentary on market conditions, or specific risk factors. The document serves solely to disclose the appointment of Dr. Zhou, highlighting his background as an entrepreneur, researcher, and former chairman of various biotechnology and health technology entities.
Investor Verification Checklist
- Verify the effective date of Dr. Xunyong Zhou's board appointment (November 26, 2025).
- Confirm Dr. Zhou's current roles at Huakang Biomedical Holdings Company Limited and Nanjing Hezhen Holding Group Co., Ltd.
- Review the Company's latest 10-K or 10-Q filings for financial metrics, as this 8-K contains no financial data.
- Check for any potential conflicts of interest given Dr. Zhou's concurrent leadership roles in other biotechnology firms.